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SUMMARY
The cyclooctadepsipeptide PF1022A derived from the fungus, Mycelia sterilia, is characterized by a broad spectrum of
activity against diﬀerent parasitic gastrointestinal nematodes of livestock. In the present work the anthelmintic activity
of PF1022A against Heligmosomoides bakeri, a widely used laboratory model was studied. Albendazole, ivermectin and
levamisole served as reference. In vitro, PF1022A showed low activity on embryonation but signiﬁcantly inhibited egg hatch
(10 and 100 μg/ml), whereas albendazole (10 and 100 μg/ml) revealed statistically signiﬁcant inhibitions of both
embryonation and egg hatch. PF1022A (1–100 μg/ml) completely inhibited larval movement at most examination points.
Comparable signiﬁcant anthelmintic activity on the larval stages ofH. bakeriwas observed with levamisole (48–100%), while
slightly lower activities were observed with ivermectin (20–92%) and albendazole (0–87%) at 1–100 μg/ml. PF1022A and
levamisole signiﬁcantly inhibited motility and egg release of adult worms, while albendazole and ivermectin failed to
demonstrate activity. Signiﬁcant worm burden reductions were achieved with PF1022A, levamisole and ivermectin in vivo.
For example, at 0·125mg/kg PF1022A a worm burden reduction of 91·8% was observed. The use of drug combinations did
not further enhance the in vitro and in vivo activity of PF1022A. In conclusion, further investigations are warranted with
PF1022A, as the drug is characterized by signiﬁcant larvicidal and nematocidal activity in vitro and in vivo.
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INTRODUCTION
Soil-transmitted helminthiases are neglected tropical
diseases caused byAscaris lumbricoides (roundworm),
Trichuris trichuria (whipworm), Strongyloides
stercoralis (threadworm) and the hookworms,
Ancylostoma duodenale and Necator americanus.
Soil-transmitted helminth infections aﬀect more
than a quarter of the human population, mostly in
low-income countries in tropical and subtropical re-
gions of the world (Bethony et al. 2006; Chan, 1997;
Hotez et al. 2007). It is diﬃcult to estimate the
amount of morbidity and mortality caused by
intestinal nematodes. In 1997 it was estimated that
intestinal nematode infections cause the loss of
39 million disability-adjusted life years (DALYs) of
which A. lumbricoides infections account for 10·5
million, T. trichuria infections for 6·4 million, and
infections with hookworm for 22·1 million (Chan,
1997). In the framework of the ongoing new Global
Burden of Disease study the global distribution and
disease burden of intestinal nematodiasis is currently
being evaluated and re-analysed (Brooker, 2010).
Soil-transmitted helminthiases control pro-
grammes aim to reduce morbidity through regular
treatment; however, only a handful of drugs are
available, albendazole, mebendazole, levamisole and
pyrantel pamoate (Keiser and Utzinger, 2010). Drug
resistance is a main concern under such high selective
pressure. Indeed, in veterinary medicine anthelmin-
tic resistance has established at relatively low treat-
ment frequencies (Coles, 1999; Coles and Klei,
1995). In addition, the currently used drugs have
several shortcomings: for example, none of the drugs
is highly eﬀective against T. trichuria when adminis-
tered at single doses (Keiser and Utzinger, 2008).
Hence, it is imperative that new anthelmintic drugs
are developed.
The cyclooctadepsipeptide PF1022A, is a natural
compound produced by fermentation of the fungus
Mycelia sterilia (Sasaki et al. 1992). Anthelmintic
activities of PF1022A and emodepside, a semi-
synthetic derivative, have been demonstrated in
several in vitro and in vivo studies against various
nematodes. For example, the larval and adult stages
of Heterakis spumosa were highly susceptible to
PF1022A (Harder et al. 1997). In a jird model,
Haemonchus contortus, Trichostrongylus colubriformis,
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and Ostertagia ostertagi were susceptible to oral
PF1022A, with declined eﬃcacies noted when
the drug was administered parenterally (Conder
et al. 1995). PF1022A was also highly active against
Toxocara canis and T. cati in dogs (Fukashe et al.
1990). Broad-spectrum anthelmintic activity has also
been demonstratedwith emodepside against the adult
stages of Heligmosomoides polygyrus, Strongyloides
ratti and Nippostrongylus brasiliensis (Harder and
von Samson-Himmelstjerna, 2002). Most importan-
tly, cyclooctadepsipeptides are active against resistant
isolates (Harder and von Samson-Himmelstjerna,
2002), which has been explained by their unique
mechanism of actions, the simultaneous stimulation
of the GABAergic neurotransmission and inhibition
of the cholinergic systems (Harder et al. 2005;Terada,
1992). In more detail, emodepside has been demon-
strated to act throughaSLO-1dependentpathway,by
activating a calcium-activated potassium channel
(Guest et al. 2007).
A combination of emodepside and praziquantel
(Profender®, Bayer AG, Leverkusen, Germany) is
marketed for use in companion-animals (Mehlhorn
et al. 2005; Schroeder et al. 2009).
The aim of this study was to further strengthen
our knowledge on the nematocidal properties of
PF1022A. We investigated the in vitro and in vivo
eﬃcacy of PF1022A against the trichostrongylid
nematode Heligmosomoides bakeri, formerly known
as H. polygyrus and Nematospiroides dubius. In vitro
inhibition of egg development, larval and adult
motility and egg release were studied following
incubation with PF1022A. Albendazole, levamisole
and ivermectin were used as reference drugs. In ad-
dition, drug combinations of PF1022A plus iver-
mectin, levamisole or albendazole were studied
in vitro. Finally, the dose-response relationships of
PF1022A, ivermectin, levamisole and albendazole as
well as combinations of PF1022A with these drugs
were studied in vivo.
MATERIALS AND METHODS
Drugs
PF1022A was obtained from Bayer AG, Monheim.
Albendazole, levamisole, and ivermectin were
purchased from Sigma Aldrich (Buchs, Switzerland).
Stock solutions of PF1022A, albendazole, levamisole
and ivermectin were prepared by dissolving 10mg
of each drug in 1ml of 99·9% dimethylsulfoxide
((DMSO), Fluka Analytical, Sigma-Aldrich).
Parasite
The infective third-stage larvae (L3) of H. bakeri
used in our work were obtained from the Swiss
Federal Institute of Technology, Zurich. The
H. bakeri life cycle was maintained in female
NMRI mice in our laboratories at the Swiss
Tropical and Public Health Institute (Basel,
Switzerland), following national and cantonal regu-
lations on animal welfare (Permit no. 2070).
L3 larvae were cultured from faeces of infected
mice using the coproculture technique described by
Burren (1980). Brieﬂy, collected faeces were pooled
together, mixed with distilled water and ﬁltered. The
ﬁltrate was centrifuged and the supernatant dis-
carded. The sieved faeces (sediment) was then thinly
smeared onto 3 moistened Whatman® 40 ﬁlter
papers, and incubated in a Petri dish for 7 days at
25 °C. After the harvest of L3 larvae, the larval sus-
pension was adjusted to a larval concentration of 30
L3 larvae per 20 μl. The L3 larvae were suspended
in distilled water and stored at 4 °C. For the larval
motility assays, L3 larvae less than 72 h old were
used.
The ﬁrst- (L1) and second-stage larvae (L2) used
for the larval motility assay were cultured directly
from eggs recovered frommice faeces. The eggs were
cultured in a Petri dish containing distilled water for
48 h. Harvested L1/L2 larvae (30 L1/L2 larvae per
20 μl) were used immediately to prevent their
development into L3 larvae. Both larval suspensions
contained 100U/ml of penicillin, 100 μg/ml strepto-
mycin (Gibco) and 12·5 μg/ml of amphotericin B
(Sigma).
Preparation of eggs
Faecal pellets of H. bakeri-infected mice were
collected over a period of 3 h using wire-bottomed
cages lined with moist paper towel. The faeces were
soaked (1:10) in 0·9% NaCl for 30min and vortexed.
The faecal mixture was then ﬁltered through a tea
strainer (0·1mm aperture) and the ﬁltrate was
centrifuged at 500 g for 5 min in a 50ml Falcon
tube (Sarstedt). The sediment was resuspended in a
25% glucose solution (α-D-glucose 96%, Aldrich
Chemistry). A layer of 1ml of distilled water was
placed on top of the faecal/glucose solution and
centrifuged at 500 g for 5 min at 15 °C. The eggs were
recovered from the interface between the distilled
water and the glucose and rinsed with distilled water.
The recovered eggs were suspended in distilled water
containing antibiotics and fungicide.
Egg hatch test
Thirty unembryonated eggs (20 μl) were placed in
48-well plates containing RPMI 1640 (470 μl) and
10 μl of the test drugs (1 to 100 μg/ml). The plates
were incubated at 25±1 °C for 40 h. Control wells
contained 1% DMSO. The egg hatch test was carried
out as described by Fonseca-Salamanca and co-
workers (Fonseca-Salamanca et al. 2003), with
minor modiﬁcations. The ovicidal eﬀect of drugs
at each concentration was quantiﬁed by counting
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embryonated and unembryonated eggs at 24 h, and
the numbers of L1/L2 larvae and unhatched eggs in
each well at the end of incubation. These data were
compared to the control wells (after correcting for
undeveloped eggs). Data-points consist of 3 inde-
pendent assays, with duplicate assay wells, for each
drug concentration. Between 4 and 6 control wells
were included per assay.
Larval motility assay
L1/L2 or L3 larvae were placed in wells (30 per well)
containing RPMI and increasing concentrations
(0·1–100 μg/ml) of the test drugs. Control wells con-
tained 1% DMSO. Larval motility was observed
under an inverted microscope (X100) and anthel-
mintic activity was recorded at 2, 24 and 48 h (L1/L2
assay) and at 2, 24, 48 and 72 h (L3 assay) after incu-
bation at 25 °C, respectively. Worms were classiﬁed
as either, 0 – inhibited, not moving/paralysed or
1 – alive, moving/twitching.
In preliminary assays, untreated L1/L2 control
larvae were observed to be actively motile at the 2 and
24 h time-points but not at the 48 h time-point.
Therefore, an external stimulation of wells at 48 h
with hot water (Satou et al. 2001) was used to evoke
motility in the L1/L2 motility assay. Brieﬂy, at the
48 h time-point 500 μl of hot water (80 °C) was added
to each well and the larval motility observed after
20–30 sec. For the L3 assay, wells were stimulated at
all 4 time-points. All externally stimulated wells were
excluded from further reading.
Percentage survival in each well was calculated
by counting treated motile and immotile larvae and
comparing them to motile larvae in control wells.
Three independent experiments were performed,
with a range of 4 to 8 assay wells for each drug
concentration and control.
L3 larval motility assay with drug combinations
The following 4 drug combinations were studied:
PF1022A (0·1 μg/ml) plus albendazole (1 μg/ml),
ivermectin (1 μg/ml) or levamisole (0·1 μg/ml) and
PF1022A (0·05 μg/ml) plus ivermectin (0·5 μg/ml).
A 24-well plate assay (1000 μl) which contained
the drug combinations, 780 μl of RPMI, 20 μl of L3
larval suspension was incubated at 25 °C and
observed 72 h post-incubation. The anthelmintic
activities of combination treatments were assessed
in 4 independent experiments, with triplicate assay
wells for each drug combination.
Adult motility assay
Six female NMRImice were infected with 150 infec-
tive L3 larvae by gavage. At 11 days post-infection
mice were killed with CO2 and the small intestine of
each mouse was removed, opened longitudinally and
incubated in pre-warmed saline. The adult worms
were retrieved by picking, and placed in Petri dishes
that contained supplemented RPMI 1640 pre-
warmed at 37 °C.
Adult worms were washed with RPMI and 2
females and 2 males were placed into each well of a
48-well plate which contained 0·5 ml phenol-red free
RPMI supplemented with 25mMHEPES, 500U/ml
penicillin, 500 μg/ml streptomycin, 0·6 μg/ml am-
photericin B and PF1022A, albendazole, ivermectin,
levamisole (100–0·1 μg/ml) or solvent (0·2%DMSO).
Each plate was incubated at 37 °C with 5% CO2
(Innova® CO-48, Newbrunswick Scientiﬁc) for 72 h.
The anthelmintic activity of tested drugs on adult
worms was quantiﬁed as described above using an
inverted microscope. The adult motility assay was
performed once, in triplicate assay wells for each
tested drug concentration and control.
Egg release
For the evaluation of the eﬀect of drugs on H. bakeri
egg release 3 female wormswere placed in eachwell of
a 48-well plate that contained supplemented RPMI
with diﬀerent concentrations of albendazole, levami-
sole, ivermectin and PF1022A. Untreated worms
served as controls. After incubation for 24 h at 37 °C
in 5% CO2, adult worms were removed and the
culture medium containing eggs was retrieved and
each well rinsed with 500 μl of distilled water. The
number of eggs released was calculated for each drug
and drug concentration by counting 4 aliquots of
20 μl from each well. The percentage reduction was
calculated by comparing drug-treated wells to control
wells.
In vivo studies
Eighty-four female NMRI mice were orally infected
with 150 infective L3 larvae. At 11 days post-
infection mice (groups of 4) were treated with single
oral doses of 0·0625, 0·125, 0·25 or 0·5 mg/kg
PF1022A, 0·25, 0·5 or 1mg/kg ivermectin, 1·25,
2·5, 5 or 10mg/kg levamisole, and 5 and 10mg/kg
albendazole. Three groups of mice (n=4 each)
received 0·0625mg/kg PF1022A combined with
0·125mg/kg ivermectin, 1·25 mg/kg levamisole or
10mg/kg albendazole. Four groups of 4 infected
but untreated mice served as controls. At 6 days
post-treatment mice were killed with CO2 and the
adult worms collected and counted as described
above.
Statistical analyses
The proportions of inhibition for egg embryonation,
hatching, worm motility and egg release were calcul-
ated as a percentage (mean±standard deviation)
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using Microsoft® Excel. The Fisher’s exact test was
used to assess statistical signiﬁcance of the diﬀerent
drugs on egg hatch test, larval motility assays (L1/L2
and L3) and adult motility assay at a 5% level of
signiﬁcance, using GraphPad Instat (version 3.10,
San Diego, CA, USA). The Kruskal-Wallis (KW)
test (Statsdirect statistical software (version 2.4.5,
Statsdirect Ltd, Cheshire, UK)) was used to compare
the medians of the H. bakeri worm counts (control
versus each of the 4 drugs at all doses tested). Diﬀer-
ences in medians were considered to be signiﬁcant at
a signiﬁcance level of 0·05. ED50 and combination
index (CI) values (Chou, 1998) were calculated using
the CompuSyn software.
RESULTS
Egg hatch test
The eﬀects of PF1022A, albendazole, ivermectin and
levamisole on embryonation and egg hatch are
summarized in Table 1. PF1022A, ivermectin and
levamisole had no signiﬁcant eﬀect on egg embry-
onation, regardless of the concentration tested. Egg
hatching was signiﬁcantly aﬀected by levamisole and
PF1022A at the 2 highest concentrations tested (100
and 10 μg/ml). The most eﬀective drug was alben-
dazole, which showed a signiﬁcant (P<0·001)
reduction in embryonation and egg hatch of un-
embryonated eggs of H. bakeri regardless of the
concentration used.
Larval motility assays
The eﬀects of PF1022A, levamisole, albendazole
and ivermectin on the motility of L1/L2 larvae of
H. bakeri are summarized in Table 2. Incubation
with1–100 μg/mlofPF1022Aresulted in a rapidpara-
lysis of L1/L2 larvae at the 2 h time-point, with none
of the larvae showing movement (P<0·001). High,
signiﬁcant activity (P<0·001) was also observed with
levamisole (0·1–100 μg/ml). A reversed inhibitory
eﬀect (92·0 versus 47·5%) was noted for the highest
concentration of levamisole tested (100 μg/ml) at the
2 and 24 h time-points. The reductions of motility
calculated for ivermectin (1–100 μg/ml) increased
from 29·5–36·5% after 2 h (P<0·001) to 79·0–92·0%
(P<0·001) after 72 h. Albendazole showed the slow-
est activity on L1/L2 larvae: while low to moderate
anthelmintic activities were observed at the 2 h and
24 h time-points (1·5–30·5% inhibition) high activi-
ties (63–87%) were observed after 48 h.
Inhibition of L3 larval motility following incu-
bation with PF1022A, albendazole, ivermectin and
levamisole are presented inTable 3. In the presence of
1–100 μg/ml of PF1022A, L3 larvae movements were
completely inhibited at most examination points.
Signiﬁcant (P<0·001) motility reductions (79–100%)
of L3 larvae were also observed for levamisole
(1–100 μg/ml) at 24–72 h post-incubation. Iver-
mectin at 1–100 μg/ml signiﬁcantly (P<0·001)
inhibited the motility of L3 larvae at the 24 h time-
point. However, after 72 h of incubation the inhibi-
tory eﬀect of ivermectin on L3 larval motility had
decreased. Albendazole showed weak to moderate
inhibitions (13·6–51%) at any of the concentrations
tested.
L3 Larval motility assay with drug combinations
In the combination treatment assays (Fig. 1),
PF1022A (0·1 μg/ml) plus ivermectin (1 μg/ml) inhi-
bited L3 larvae movement by 99·3% at 72 h. Using
half of the concentrations (0·05 μg/ml PF1022A plus
0·5 μg/ml ivermectin), L3 larval motility was inhib-
ited by 76·9% 72 h post-incubation. Low eﬃcacies
(65 and 57%) were observed with combination treat-
ments of PF1022A (0·1 μg/ml) plus levamisole
(0·1 μg/ml) or albendazole (1 μg/ml), respectively.
Analysis based on the Chou-Talalay CI theorem
showed that none of the combinations were additive
or synergistic but rather revealed antagonistic eﬀects
(CI>1·2).
Adult motility assay
The activity of PF1022A, ivermectin, albendazole
and levamisole against adult H. bakeri is presented
in Fig. 2. The mean motility rate of adult H. bakeri
in control wells at 72 h was 93·8%, which was
Table 1. Eﬃcacy of PF1022A, albendazole,
ivermectin and levamisole on embryonation and
hatching of unembryonated eggs of
Heligmosomoides bakeri
(Each inhibition (%) represents the mean (standard
deviation) of 3 independent experiments, with each drug
concentration carried out in duplicate.)
Drug
Concen-
tration
(μg/ml)
Inhibition (%)
of embryonation
at 24 h (S.D.)
Inhibition (%)
of hatching
at 40 h (S.D.)
Control — 0 0
PF1022A 100 2·0 (2·0) 4·7 (2·3)
10 1·0 (1·0) 46·7 (1·5)*
1 2·0 (2·0) 18·0 (8·5)*
Albendazole 100 100* 100*
10 99 (1·7)* 100*
1 25·3 (37·8)* 43·7 (49·2)*
Ivermectin 100 4·7 (5·0) 5·0 (1·7)
10 1·0 (1·0) 2·7 (0·6)
1 1·0 (1·0) 4·7 (1·5)
Levamisole 100 0·3 (0·6) 69·7 (10·2)*
10 1·3 (2·3) 67·0 (5·3)*
1 4·0 (1·0) 16·3 (4·6)*
* Statistically signiﬁcant (P<0·001).
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Table 2. In vitro eﬀect of PF1022A, albendazole, ivermectin and levamisole on the motility of L1/L2 larvae of Heligomosomoides bakeri
(Inhibition (%) data (mean±standard deviation) from 3 independent experiments with duplicate assay wells; except for albendazole and ivermectin at 0·1 μg/ml, with data calculated
from a single assay.)
Drug Control
PF1022A Albendazole Ivermectin Levamisole
Inhibition of motility (%) (S.D.)
Concentration
(μg/ml)
100 10 1 0·1 100 10 1 0·1 100 10 1 0·1 100 10 1 0·1
Time (h) 2 0 100* 100* 100* 6·5
(0·7)
1·5
(2·1)
3·0
(4·2)
0 NT 36·5
(33·2)*
36·0
(31·1)*
29·5
(29·0)*
NT 92·0
(7·1)*
94·5
(3·5)*
89·5
(0·7)*
11·0
(5·7)*
24 0 100* 100* 100* 17·5
(2·1)**
15·5
(9·2)
30·5
(27·6)*
16·5
(13·4)**
18·8 36·0
(5·7)*
34·0
(2·8)*
30·0
(15·6)*
10·0 47·5
(13·4)*
98·5
(2·1)*
100* 31·5
(3·5)*
48 0 100* 100* 100* 57·5
(12·0)
87·0
(2·8)*
63·0
(7·1)
79·0
(5·7)*
18·8 92·0
(11·3)*
85·5
(10·6)*
79·0
(5·7)**
0 98·0
(2·8)*
100* 100* 64·5
(30·4)
* Statistically signiﬁcant (P<0·001) and ** (P<0·05). NT: not tested.
Table 3. In vitro eﬃcacy of PF1022A, albendazole, ivermectin and levamisole against L3 larvae of Heligmosomoides bakeri
(Each data-point represents the mean ((±standard deviation), with 3–8 assay wells from 3 independent trials); except for albendazole and ivermectin at 72 h, which is from a single assay.)
Drug Control
PF1022A Albendazole Ivermectin Levamisole
Inhibition of motility (%) (SD)
Concentration
(μg/ml)
100 10 1 0·1 100 10 1 0·1 100 10 1 0·1 100 10 1 0·1
Time (h) 2 0 100* 84·6
(18·7)*
26·3
(29·0)
26·6
(14·3)
23·3
(7·8)**
23·6
(14·6)**
15·6
(11·3)*
13·6
(7·1)*
85·1
(18·9)*
68·5
(11·6)*
19·6
(9·0)**
19·5
(15·3)**
76·0
(19·6)*
48·3
(26·5)
22·7
(11·1)
19·1
(11·9)**
24 0 100* 100* 100* 21·0
(9·9)**
33·0
(15·4)*
16·0
(6·6)**
22·0
(6·5)
19·0
(6·5)
74·0
(23·3)*
67·0
(16·8)*
88·0
(3·6)*
29·6
(4·3)
90·0
(17·3)*
91·0
(12·5)*
79·0
(17·1)*
25·5
(12·0)*
48 0 100* 100* 100* 55·0
(5·7)
43·7
(19·6)*
39·0
(16·5)**
41·0
(14·2)**
23·3
(5·8)
56·7
(5·1)*
65·0
(2·0)*
66·0
(5·1)*
20·0
(9·8)
100* 100* 96·0
(6·7)*
65·0
(4·2)*
72 0 100* 100* 100* 57·0
(8·5)
51·0 45·0 48·0 21·2
(11·8)
41·0 56·0 64·0** 25·2
(10·9)
100* 100* 100* 96·0
(3·5)*
* Statistically signiﬁcant (P<0·001) and ** (P<0·05).
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comparable to the motility at commencement of the
assays. At 72 h post-incubation with 100 μg/ml of the
test drugs, PF1022A demonstrated moderate (67·2%
(P<0·05)) activity against adult worms of H. bakeri,
levamisole showed a slight inhibition of 12·5%,
while no activity was observed with ivermectin and
albendazole (EC50>100 μg/ml for albendazole and
ivermectin). At 10 μg/ml, PF1022A and levamisole
reduced movement of adult worms by 78·1%
(P=0·001) and 100% (P<0·001), respectively, at
72 h. Following incubation with 1 μg/ml of drugs,
only levamisole demonstrated signiﬁcant (P<0·05
and <0·001) activity at all examination points. For
PF1022A and levamisole EC50 values of 2.7 and
1.3 μg/ml, respectively were calculated.
Egg release
The eﬀect of PF1022A, ivermectin and levamisole on
the egg production of female H. bakeri worms is
shown in Fig. 3. Ivermectin failed to inhibit the egg
production at any concentration tested, while alben-
dazole showed only a moderate activity at 100 μg/ml
(49·0%). Worms incubated in the presence of
PF1022A showed reductions in the number of eggs
ranging from 74·9% (10 μg/ml) to 80·9% (100 μg/ml).
The highest activities were observed following
exposure to levamisole, which reduced the egg release
at all concentrations tested. For example, at 10 μg/ml
of levamisole, 10 eggs were released within 24 h,
which was a 95·2% reduction compared to control.
In vivo studies
Monotherapy. Worm burden reductions of
90·4–95·9% were achieved with PF1022A at doses
of 0·125mg/kg and above. At 0·0625mg/kg
PF1022A a low worm burden reduction of 24·5%
was observed. The worm burden reductions in
PF1022A-treated mice were statistically signiﬁcant
(KW=8·629, p=0·003). An ED50 of 0·07mg/kg was
calculated for PF1022A. Similarly, when ivermectin
(0·125 −1mg/kg) was given to H. bakeri-infected
mice signiﬁcant worm burden reductions of 53·7–
98·6% (ED50 of 0·11mg/kg) (KW=11·324,
p<0·001) were documented. Levamisole adminis-
tration (1·25–10mg/kg) resulted also in high, signiﬁ-
cant worm burden reductions of 61·5–100% (ED50
of 1·05mg/kg). A moderate, non-signiﬁcant worm
burden reduction was achieved, when a single oral
dose of 10mg/kg albendazole was given toH. bakeri-
infected mice (ED50 of albendazole 9·8 mg/kg
(Table 4)).
Combined treatment. Since we were interested to
learn whether PF1022A combinations might act
additively or synergistically in vivo median eﬀective
doses of PF1022A (0·0625 mg/kg) were combined
with the partner drugs following the constant ratio
combination design (Chou, 1998). Combinations of
PF1022A and albendazole (10 mg/kg) had no eﬀect
on the worm burden and a lower activity than alben-
dazole or PF1022A monotherapy. Moderate worm
burden reductions of 59·1 and 66·3% were observed
with PF1022A plus ivermectin (0·125mg/kg) or
levamisole (1·25mg/kg), respectively, which were,
however, not signiﬁcantly higher than the single
drugs (Table 4). Since no additive or synergistic
eﬀects were observed further doses were not tested
for any of the combinations.
DISCUSSION
The use of in vitro assays to screen for lead com-
pounds with anthelmintic activity has been pivotal to
drugdiscovery anddevelopment forhelminth chemo-
therapy (Keiser, 2010). In vitro helminth drug assays
are ethical, often simple, of low cost and allow for
medium-throughput screening of compounds
(Keiser, 2010). In this study, we conducted diﬀerent
in vitro assays, such as the egg hatch test, larval
motility assays and the adult motility assay including
studies on egg production to compare the eﬃcacy of
PF1022A against multiple life-cycle stages of the
murine parasite H. bakeri. Albendazole, ivermectin
and levamisole were used as reference drugs in these
experiments. In vivo studies complemented our
work.
PF1022A showed excellent nematocidal properties
against the diﬀerent life-cycle stages ofH. bakeri.Our
ﬁnding is in agreement with previous reports, which
Fig. 1. Eﬃcacy of combination treatment against L3
larvae of Heligmosomoides bakeri 72 h post-incubation.
The grey bars represent the partner drugs (albendazole,
ivermectin or levamisole), the black bars represent
PF1022A and the white bars represent drug
combinations. Data-points of combination treatment
represent 4 independent experiments consisting of
triplicate assay wells for each drug concentration. Error
bars indicate standard deviation.
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documented high anthelminthic activities of
PF1022A (Harder et al. 1997; Harder and von
Samson-Himmelstjerna, 2002). PF1022 showed
better eﬃcacies than the standard drugs alben-
dazole, ivermectin or levamisole, which is in line
with ﬁndings documented against adult females of
H. contortus (Conder, et al. 1995).
In the larval motility assays, PF1022A showed the
highest activity among all drugs tested. PF1022Awas
highly eﬀective against both L1/L2 and L3 larvae.
Similarly, levamisole produced pronounced eﬀects,
while albendazole and ivermectin showed slightly
lower activities againstL1/L2 andL3 larvae. Interest-
ingly, L1/L2 larvae incubated with levamisole
(100 μg/ml) showed no movement at the 2 h time-
points, regained movement at the 24 h time-point and
became again immotile at 48 h. This phenomenon,
also termed ‘tachyphlaxy’, has been demonstrated
with levamisole usingL3 larvae ofOstertagia ostertagi
(Geerts et al. 1989) and following incubation of L3
larvae of Ancylostoma caninum with pyrantel (Kopp
et al. 2008). This ﬁnding was not observed with
H. bakeri L3 larvae at the highest concentration of
levamisole tested.
The nematocidal activity observed with the test
drugs against adult H. bakeri in vitro was similar to
the ﬁndings observed with the free-living stages.
PF1022A demonstrated the highest activity against
adult worms at concentrations of 100 and 10 μg/ml,
while levamisole was the most eﬃcacious drug at
1 μg/ml. The contradictory ﬁndings observed with
levamisole (inhibition observed with 10 and 1 μg/ml
but no activity observed with 100 μg/ml) might be
due to the cholinergic mechanism of action of the
drug. A similar result was obtained with tribendimi-
dine; an anthelmintic drug with a related mechanism
of action, using the same assay format (unpublished
observations). Ivermectin was the least active drug
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Fig. 2. Eﬀect of PF1022A, ivermectin, levamisole and albendazole against adult worms of Heligmosomoides bakeri at
100 μg/ml (white bars), 10 μg/ml (black bars) and 1 μg/ml (grey bars). Data-points derived from a single assay; with 3
replicate wells for each drug concentration and control. Error bars indicate standard deviation.
Fig. 3. Eﬃcacy of albendazole, ivermectin, levamisole
and PF1022A on the egg release of female
Heligmosomoides bakeri 24 h post-incubation. Controls
(white bars), 100 μg/ml (white bar), 10 μg/ml (black bar)
and 1 μg/ml (grey bar); error bars indicate standard
deviation. Data-points derived from a single assay with
3 to 10 replicate wells for each drug concentration and
control. The activity of ivermectin, levamisole and
PF1022A on the egg release was calculated in comparison
to control (a), and albendazole was analysed in
comparison to control (b).
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in vitro, with treated adult H. bakeri comparable to
control worms. The inability of ivermectin to aﬀect
adultH. bakeri in vitro was also conﬁrmed in our egg
release studies. However, interestingly, ivermectin
achieved almost complete adult worm burden reduc-
tions in vivo, a ﬁnding, which is in line with previous
publications (Wahid et al. 1989; Njoroge et al. 1997).
Highwormburden reductions against adultH. bakeri
in mice were also observed with PF1022A at doses as
low as 0·125mg/kg. A previous study has shown that
the semi-synthetic derivative of PF1022A, emodep-
side was not only active against the adult stages of
H. bakeri but achieved complete worm burden re-
duction, when administered as early as 2 days post-
infection (Harder and von Samson-Himmelstjerna,
2001). Cure of H. bakeri-infected mice was also
observed with levamisole at 5 and 10mg/kg conﬁr-
ming previous results (Chimwani and Britt, 1986).
The lowest activity againstH. bakeri in vivo was seen
with albendazole.
The egg hatch test is a common method to de-
tect benzimidazole and levamisole resistance (von
Samson-Himmelstjerna et al. 2009). The incubation
of H. bakeri eggs with our test drugs revealed
an ovicidal eﬀect of PF1022A and levamisole.
Albendazole inhibited egg development at all tested
concentrations.
To our knowledge we have, for the ﬁrst time, tested
the eﬀect of PF1022A drug combinations against
H. bakeri in vitro and in vivo. None of the drug
combinations tested showed additive or synergistic
but rather antagonistic eﬀects on L3 larvae move-
ment. These ﬁndings were also conﬁrmed in our in
vivo studies. None of the combinations tested in our
study resulted in signiﬁcantly higher worm burden
reductions when compared to monotherapy. On
the other hand, additive eﬀects were observed in
H. bakeri-infected mice in a previous study when
emodepside was combined with piperazine (Nicolay
et al. 2000). Why PF1022A showed decreased
Table 4. In vivo eﬃcacy of PF1022A, ivermectin levamisole and albendazole and combinations of
PF1022A and ivermectin, PF1022A and levamisole, and PF1022A and albendazole against adult
Heligmosomoides bakeri
(S.D., standard deviation, KW: Kruskal Wallis.)
Treatment Drug
Dose
(mg/kg)
(single)
Number
of animals
cured
Mean
number of
worms (SD)
Total worm
burden
reduction (%)
(95% CI)
ED50
(mg/kg) KW P-value
Control 1 — 0 18·3 (9·6) — — —
Control 2 — 0 9·0 (8·4) — — —
Control 3 — 0 23·8 (18·7) — — —
Control 4 — 0 10·4 (7·8) — — —
Monotherapy PF1022A 0·5a 2 0·75 (0·95) 95·9 (85–99) 0·07 8·629 0·003
0·25a 1 1·75 (2·2) 90·4 (75–97)
0·125a 2 1·5 (2·4) 91·8 (77–98)
0·0625b 0 6·8 (4·0) 24·5 (0–64)
Ivermectin 1a 3 0·25 (0·5) 98·6 (90–100) 0·11 11·324 <0·001
0·5b 2 1·5 (2·4) 83·3 (48–96)
0·25b 1 1·25 (0·95) 86·1 (54–97)
0·125c 0 11·0 (3·3) 53·7 (23–72)
Levamisole 10b 4 0 100 (85–100) 1·05 17·826 <0·001
5b 4 0 100 (85–100)
2·5c 3 0·25 (0·5) 98·9 (93–100)
1·25d 0 4·0 (3·2) 61·5 (16–83)
Albendazole 10c 0 11·25 (3·8) 52·6 (22–72) 9·8 0·456 0·499
5d 0 9·8 (4·6) 6·3 (0–45)
Combination
chemotherapy
PF1022A 0·0625mg/kg
plus albendazole
10mg/kgd
1 11·5 (14·7) 0 (0–38) — —
PF1022A 0·0625mg/kg
plus ivermectin
0·125mg/kgd
1 4·3 (3·3) 59·1 (12–82) 0·968 0·325
PF1022A 0·0625mg/kg
plus levamisole
1·25 mg/kgd
1 3·5 (3·9) 66·3 (24–86) 2·215 0·137
a Versus control 1.
b Versus control 2.
c Versus control 3.
d Versus control 4.
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activities, when combined with albendazole, levami-
sole or ivermectin cannot be explained at the
moment, hence further studies should be launched.
In conclusion, our work conﬁrmed thatH. bakeri is
an excellent model to study the anthelmintic activity
of test drugs. We have demonstrated that L1/L2, L3
larvae as well as adultH. bakeri are suitable stages for
in vitro testing. Our study provides a rationale to
further study PF1022A as a potential novel anthel-
mintic drug for the treatment of STH. We docu-
mented that PF1022A has signiﬁcant larvicidal and
nematocidal activity in vitro and the drug revealed the
highest activities in vivo when compared to the
reference drugs albendazole, levamisole and ivermec-
tin. In the light of our promising ﬁndings with
PF1022A further investigations should be launched
possibly in a next step against the target nematodes
the hookworms, Trichuris spp., Strongyloides spp.
and Ascaris spp. in permissive hosts.
ACKNOWLEDGEMENTS
We are grateful to the Swiss National Science Foundation
(Project no. PPOOA-114941), Swiss Tropical and Public
Health Institute and Bayer HealthCare AG for ﬁnancial
support.
REFERENCES
Bethony, J., Brooker, S., Albonico, M., Geiger, S.M., Loukas, A.,
Diemert, D. and Hotez, P. J. (2006). Soil-transmitted helminth infec-
tions: ascariasis, trichuriasis, and hookworm. Lancet 367, 1521–1532.
Brooker, S. (2010). Estimating the global distribution and disease burden of
intestinal nematode infections: adding up the numbers – a review.
International Journal for Parasitology 40, 1137–1144.
Burren, C. H. (1980). A method for obtaining large numbers of clean
infective larvae of Nematospiroides dubius. Zeitschrift für Parasitenkunde 62,
111–112.
Chan, M. S. (1997). The global burden of intestinal nematode infections –
ﬁfty years on. Parasitology Today 13, 438–443.
Chimwani, D.M. and Britt, D. P. (1986). The eﬃcacy of levamisole
administered orally or parenterally against Heligmosomoides polygyrus in
mice. Journal of Helminthology 60, 99–104.
Chou, T. C. (1998). Drug combinations: from laboratory to practice.
Journal of Laboratory and Clinical Medicine 132, 6–8.
Coles, G. C. (1999). Anthelmintic resistance and the control of worms.
Journal of Medical Microbiology 48, 323–325.
Coles, G. C. and Klei, T. R. (1995). Animal parasites, politics and
agricultural research. Parasitology Today 11, 276–278.
Conder, G. A., Johnson, S. S., Nowakowski, D. S., Blake, T. E.,
Dutton, F. E., Nelson, S. J., Thomas, E.M., Davis, J. P. and
Thompson, D. P. (1995). Anthelmintic proﬁle of the cyclodepsipeptide
PF1022A in in vitro and in vivo models. Journal of Antibiotics (Tokyo) 48,
820–823.
Fonseca-Salamanca, F., Martinez-Grueiro, M.M. and Martinez-
Fernandez, A. R. (2003). Nematocidal activity of nitazoxanide in
laboratory models. Parasitology Research 91, 321–324.
Fukashe, T., Koike, T., Chinone, S., Akihama, S., Iagake, H.,
Takagi, M., Shimizu, T., Yaguchi, T., Sasaki, T. and Okada, T.
(1990). Anthelmintic eﬀects of PF1022, a new cyclic depsipeptide, on the
intestinal parasitic nematodes in dogs and cats. Proceedings of the 110th
Meeting of the Japanese Society Veterinary Science, p. 122, Abstract.
Geerts, S., Brandt, J., Borgsteede, F. H. and Van Loon, H.
(1989). Reliability and reproducibility of the larval paralysis test as an
in vitro method for the detection of anthelmintic resistance of nematodes
against levamisole and morantel tartrate. Veterinary Parasitology 30,
223–232.
Guest, M., Bull, K., Walker, R. J., Amliwala, K., O’Connor, V.,
Harder, A., Holden-Dye, L. and Hopper, N. A. (2007). The calcium-
activated potassium channel, SLO-1, is required for the action of the novel
cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis
elegans. International Journal for Parasitology 37, 1577–1588.
Harder, A., Holden-Dye, L., Walker, R. and Wunderlich, F. (2005).
Mechanisms of action of emodepside. Parasitology Research 97 (Suppl 1),
S1–S10.
Harder, A., Londershausen, M. and Mehlhorn, H. (1997). The four
larval stages and the adults of Heterakis spumosa are impaired by the
anthelminthic cyclodepsipeptide PF1022A. Zentralblatt für Bakteriologie
286, 212.
Harder, A. and von Samson-Himmelstjerna, G. (2001). Activity of the
cyclic depsipeptide emodepside (BAY 44-4400) against larval and adult
stages of nematodes in rodents and the inﬂuence on worm survival.
Parasitology Research 87, 924–928.
Harder, A. and von Samson-Himmelstjerna, G. (2002).
Cyclooctadepsipeptides – a new class of anthelmintically active compounds.
Parasitology Research 88, 481–488.
Hotez, P. J., Molyneux, D. H., Fenwick, A., Kumaresan, J.,
Sachs, S. E., Sachs, J. D. and Savioli, L. (2007). Control of neglected
tropical diseases. New England Journal of Medicine 357, 1018–1027.
Keiser, J. (2010). In vitro and in vivo trematode models for chemother-
apeutic studies. Parasitology 137, 589–603.
Keiser, J. and Utzinger, J. (2010). The drugs we have and the drugs
we need against major helminth infections. Advances in Parasitology 73,
197–230.
Keiser, J. and Utzinger, J. (2008). Eﬃcacy of current drugs against soil-
transmitted helminth infections: systematic review and meta-analysis.
Journal of the American Medical Association 299, 1937–1948.
Kopp, S. R., Coleman, G. T., McCarthy, J. S. and Kotze, A. C. (2008).
Application of in vitro anthelmintic sensitivity assays to canine parasitology:
detecting resistance to pyrantel in Ancylostoma caninum. Veterinary
Parasitology 152, 284–293.
Mehlhorn, H., Schmahl, G., Frese, M., Mevissen, I., Harder, A. and
Krieger, K. (2005). Eﬀects of a combination of emodepside and
praziquantel on parasites of reptiles and rodents. Parasitology Research 97
(Suppl. 1), S65–S69.
Nicolay, F., Harder, A., von Samson-Himmelstjerna, G. and
Mehlhorn, H. (2000). Synergistic action of a cyclic depsipeptide and
piperazine on nematodes. Parasitology Research 86, 982–992.
Njoroge, J.M., Scott, M. E. and Jalili, F. (1997). The eﬃcacy of
ivermectin against laboratory strains of Heligmosomoides polygyrus
(Nematoda). International Journal for Parasitology 27, 439–442.
Sasaki, T., Takagi, M., Yaguchi, T., Miyadoh, S., Okada, T. and
Koyama, M. (1992). A new anthelmintic cyclodepsipeptide, PF1022A.
Journal of Antibiotics (Tokyo) 45, 692–697.
Satou, T., Koga, M., Koike, K., Tada, I. and Nikaido, T. (2001).
Nematocidal activities of thiabendazole and ivermectin against the larvae
of Strongyloides ratti and S. venezuelensis. Veterinary Parasitology 99,
311–322.
Schroeder, I., Altreuther, G., Schimmel, A., Deplazes, P., Kok, D. J.,
Schnyder, M. and Krieger, K. J. (2009). Eﬃcacy of emodepside plus
praziquantel tablets (Profender tablets for dogs) against mature and
immature cestode infections in dogs. Parasitology Research 105 (Suppl. 1),
S31–S38.
Terada, M. (1992). Neuropharmacological mechanism of PF1022A, an
antinematode anthelminthic with a new structure of cyclic depsipeptide, on
Angiostrongylus cantonensis and isolated frog rectus. Japanese Journal of
Parasitology 41, 108–117.
von Samson-Himmelstjerna, G., Coles, G. C., Jackson, F., Bauer, C.,
Borgsteede, F., Cirak, V. Y., Demeler, J., Donnan, A., Dorny, P.,
Epe, C., Harder, A., Hoglund, J., Kaminsky, R., Kerboeuf, D.,
Kuttler, U., Papadopoulos, E., Posedi, J., Small, J., Varady, M.,
Vercruysse, J. andWirtherle, N. (2009). Standardization of the egg hatch
test for the detection of benzimidazole resistance in parasitic nematodes.
Parasitology Research 105, 825–834.
Wahid, F. N., Behnke, J.M. and Conway, D. J. (1989). Factors aﬀecting
the eﬃcacy of ivermectin against Heligmosomoides polygyrus
(Nematospiroides dubius) in mice. Veterinary Parasitology 32, 325–340.
1201The eﬃcacy of cyclooctadepsipeptide PF1022A against H. bakeri
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S003118201100076X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:06:52, subject to the Cambridge Core terms of use, available at
